earningsupdate

$SKH FORECAST CUT 9% – MARKET REPRICING LONG-TERM CONTRACTS 🔍

Target: 3,800,000 KRW 🚀

Korea Investment Securities lowered SK Hynix's 2026 and 2027 operating profit forecasts by 9% and 11%, yet maintained the target price. The 75% operating margin remains at historical highs — the cut is about contract structure, not demand. HBM demand still strong from AI server expansion.

Long-term supply contracts lock in cash flow but cap upside from spot price spikes. This shifts the narrative from memory scarcity to pricing certainty. Can the market still re-rate Hynix as long-term contracts become the industry norm?

Not financial advice. Always manage your risk.

#SKH #MemoryChips #AIHardware #EarningsUpdate

💎

CME Group’s record quarter says the hedging trade is still alive $CMECME printed record revenue of $1.88B, net income of $1.154B, and adjusted EPS of $3.36 as average daily volume jumped 22% to 36.2M contracts. That tells you institutions are still paying up for protection, and the demand is widening globally, not just in the U.S. The cautious stock reaction looks more like elevated expectations than a broken story.

Not financial advice. Manage your risk and protect your capital.

#EarningsUpdate #MarketInsights #CME #Trading #Stocks

✓

CME Group’s record quarter says the hedging trade is still alive $CMECME printed record revenue of $1.88B, net income of $1.154B, and adjusted EPS of $3.36 as average daily volume jumped 22% to 36.2M contracts. That tells you institutions are still paying up for protection, and the demand is widening globally, not just in the U.S. The cautious stock reaction looks more like elevated expectations than a broken story.

Not financial advice. Manage your risk and protect your capital.

#EarningsUpdate #MarketInsights #CME #Trading #Stocks

✓

CME Group posted a record quarter as global hedging demand stayed elevated

🌐 CME Group closed Q1 2026 with record revenue of $1.88 billion, net income of $1.154 billion, and adjusted EPS of $3.36, showing that derivatives trading activity remained very strong in a highly volatile environment.

📈 The biggest highlight was average daily volume rising to 36.2 million contracts, up 22% year over year, with records set across all six asset classes. International volume also climbed 30%, signaling that hedging demand outside the U.S. continues to expand.

🧩 Margins remained exceptionally high, while transaction fee and market data revenue both reached new highs. Even though the stock reaction after the release was somewhat cautious because expectations were already elevated, the broader picture still shows CME benefiting directly from a prolonged period of macro and geopolitical uncertainty.

#EarningsUpdate #MarketInsights $ZEN $TON $WIN

Evotec draws attention with a strong Q4, but keeps a cautious tone for 2026

📈 Evotec closed Q4 2025 with a clear improvement as revenue reached €253.3 million, up 14.5% year over year, while adjusted EBITDA jumped to €58.0 million. Gross margin also improved sharply to 31.0%, pointing to much better earnings quality than a year earlier.

🧬 The main driver came from Just-Evotec Biologics, especially thanks to the €65 million license payment tied to the Sandoz deal, while the drug discovery and preclinical segment remained under pressure. This suggests current growth is being led more by biologics than by a broad-based recovery across the business.

⚙️ Although FY2025 still landed near the high end of previous guidance, the 2026 outlook remains cautious, with revenue projected at €700–780 million and adjusted EBITDA at just €0–40 million. That signals Evotec is accepting a transition year in order to execute its Horizon restructuring plan.

🔭 Over the longer term, the company still targets more than €1 billion in revenue by 2028 and an EBITDA margin above 20%. The story here is therefore not just one strong quarter, but whether the restructuring can turn into profitable growth from 2027 onward.

#StockInsight #EarningsUpdate $BTC $ETH $BNB